US2008057590A1PendingUtilityA1

Markers associated with arteriovascular events and methods of use thereof

55
Assignee: URDEA MICKEYPriority: Jun 7, 2006Filed: Jun 7, 2007Published: Mar 6, 2008
Est. expiryJun 7, 2026(expired)· nominal 20-yr term from priority
Inventors:Mickey S. UrdeaMichael P. MckennaPatrick A. Arensdorf
G01N 33/74G01N 2800/32G16H 50/30G01N 2800/324Y02A90/10G01N 2800/52G01N 2800/325G01N 33/6893G01N 2800/50G01N 33/6845
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.

Claims

exact text as granted — not AI-modified
1 . A method for evaluating the risk of a cardiovascular event for a subject comprising 
 measuring at least three component ARTERIORISKMARKERS for the individual selected from the component ARTERIORISKMARKERS within the groups consisting of Core Markers I, Core Markers II, Traditional Laboratory Risk Factors, Clinical Parameters, Supplemental Markers I, and Supplemental Markers II, provided at least one component ARTERIORISKMARKER is selected from the component ARTERIORISKMARKERS within Core Markers I.    
     
     
         2 . The method of  claim 1 , comprising measuring at least two component ARTERIORISKMARKERS within Core Markers I.  
     
     
         3 . The method of  claim 1 , comprising measuring at least three component ARTERIORISKMARKERS within Core Markers I.  
     
     
         4 . The method of  claim 1  wherein the component ARTERIORISKMARKER selected from Core Marker I is POMC.  
     
     
         5 . The method of  claim 1  wherein the risk evaluation comprises calculating an index value.  
     
     
         6 . The method of  claim 5  wherein th index value is correlated with the risk of a cardiovascular event.  
     
     
         7 . The method of  claim 1  wherein the risk evaluation comprises normalizing the component ARTERIORISKMARKER measurements to reference values.  
     
     
         8 . A method for evaluating the risk of a cardiovascular event for a subject comprising measuring at least two component ARTERIORISKMARKERS for the individual selected from the component ARTERIORISKMARKERS within Core Markers I  
     
     
         9 . The method of  claim 8  further comprising the measurement of at least one component ARTERIORISKMARKER within Clinical Parameters.  
     
     
         10 . The method of  claim 8  further comprising the measurement of at least one component ARTERIORISKMARKER within Traditional Laboratory Risk Factors.  
     
     
         11 . The method of  claim 8  further comprising the measurement of at least one component ARTERIORISKMARKER within Core Markers II.  
     
     
         12 . The method of  claim 9  further comprising the measurement of at least one component ARTERIORISKMARKER within Traditional Laboratory Risk Factors and Core Markers II.  
     
     
         13 . The method of  claim 8  further comprising at least two component ARTERIORISKMARKERS for the individual selected from the component ARTERIORISKMARKERS within Clinical Parameters, Traditional Laboratory Risk Factors, Core Markers II, Supplemental Markers I, Supplemental Markers II, Additional Markers I, Additional Markers II.  
     
     
         14 . The method of  claim 8  further comprising at least three component ARTERIORISKMARKERS for the individual selected from the component ARTERIORISKMARKERS within Clinical Parameters, Traditional Laboratory Risk Factors, Core Markers II, Supplemental Markers I, Supplemental Markers II, Additional Markers I, Additional Markers II.  
     
     
         15 . The method of any of claims  8 - 14  comprising measurement of at least three component ARTERIORISKMARKERS for the individual selected from the component ARTERIORISKMARKERS within Core Markers I  
     
     
         16 . The method of  claim 8  wherein the one component ARTERIORISKMARKER selected from Core Marker I is POMC.  
     
     
         17 . A method for evaluating the risk of a cardiovascular event for a subject comprising measurement of POMC for the individual.  
     
     
         18 . The method of  claim 17  further comprising measurement of HDLC for the subject.  
     
     
         19 . The method of  claim 17  or  18  further comprising measurement of at least one Clinical Parameter for the subject.  
     
     
         20 . The method of  claim 19  wherein said Clinical Parameter is Age or BMI  
     
     
         21 . The method of  claim 17  or  18  comprising measurement of Age and BMI for the subject.  
     
     
         22 . The method of  claim 17  or  18  comprising measurement of VEGF for the subject.  
     
     
         23 . The method of  claim 17  or  18  comprising measurement of CCL2 for the subject.  
     
     
         24 . The method of  claim 17  or  18  comprising measurement of IL6ST or IL18 or LEP.  
     
     
         25 . The method of  claim 17  or  18  comprising measurement of VEGF, CCL2, and the Clinical Parameters Age and BMI.  
     
     
         26 . A kit comprising at least one reagent for the detection or quantification of POMC.  
     
     
         27 . A kit comprising reagents for the detection or quantification of two or more component ARTERIORISKMARKERS selected from the group consisting of POMC, HDLC, VEGF, CCL2, IL6ST, IL8, and LEP.  
     
     
         28 . The kit of  claim 27  for the detection or quantification of three or more of the component ARTERIORISKMARKERS selected from the group consisting of POMC, HDLC, VEGF, CCL2, IL6ST, IL8, and LEP.  
     
     
         29 . The kit of  claim 27  for the detection or quantification of four or more of the component ARTERIORISKMARKERS selected from the group consisting of POMC, HDLC, VEGF, CCL2, IL6ST, IL8, and LEP.  
     
     
         30 . The kit of  claim 27  comprising reagents for the detection or quantification of POMC and HDLC.  
     
     
         31 . The kit of  claim 27  comprising reagents for the detection or quantification of POMC and VEGF.  
     
     
         32 . The kit of  claim 27  comprising reagents for the detection or quantification of POMC and CCL2  
     
     
         33 . The kit of  claim 27  comprising reagents for the detection or quantification of HDLC and VEGF.  
     
     
         34 . The kit of  claim 27  comprising reagents for the detection or quantification of HDLC and CCL2.  
     
     
         35 . The kit of  claim 27  comprising reagents for the detection or quantification of VEGF and CCL2.  
     
     
         36 . The kit of  claim 27  comprising reagents for the detection or quantification of POMC, HDLC, and VEGF.  
     
     
         37 . The kit of  claim 27  comprising reagents for the detection or quantification of POMC, HDLC, and CCL2.  
     
     
         38 . The kit of  claim 27  comprising reagents for the detection or quantification of POMC, VEGF, and CCL2.  
     
     
         39 . The kit of  claim 27  comprising reagents for the detection or quantification of POMC, HDLC, VEGF, and CCL2.  
     
     
         40 . A kit that comprises 
 a. Reagents for measuring 3 or more component ARTERIORISKMARKERS in a sample from the subject selected from the component ARTERIORISKMARKERS within the group consisting of Core Markers I, Core Markers II, Traditional Laboratory Risk Factors, Supplemental Markers I, and Supplemental Markers II, wherein at least two component ARTERIORISKMARKERS are selected from the component ARTERIORISKMARKERS within Core Markers I and Core Markers II; and    b. Instructions for use in calculating the index value that evaluates the risk of a cardiovascular event in a subject.    
     
     
         41 . The kit of  claim 40 , for use with an instrument.  
     
     
         42 . The kit of  claim 40 , wherein at least one of said reagents comprises a detectable label.  
     
     
         43 . The method of  claim 1  wherein the measurement of at least one of the component ARTERIORISKMARKERS selected is unaffected by treatment of the subject with one or more therapeutic interventions.  
     
     
         44 . The method of  claim 1  wherein the measurement of at least one of the component ARTERIORISKMARKERS selected is affected by treatment of the subject with one or more therapeutic interventions.  
     
     
         45 . In a method of evaluating the risk of a cardiovascular event in a subject by measuring one or more of Clinical Parameters and Traditional Laboratory Risk Factors, the improvement comprising: 
 a. Measuring at least one component ARTERIORISKMARKER in a sample from the subject selected from the -component ARTERIORISKMARKERS within the group consisting of Core Markers I and Core Markers II; and    b. evaluating the risk of developing a cardiovascular event in the subject.    
     
     
         46 . The method of  claim 45 , wherein at least two of the component ARTERIORISKMARKERS are selected from Core Markers I and Core Markers II.  
     
     
         47 . The method of  claim 45 , wherein the at least one component ARTERIORISKMARKER is selected from Core Markers I.  
     
     
         48 . The method of  claim 45 , wherein the risk evaluation comprises calculating an index value using a formula.  
     
     
         49 . The method of  claim 45 , wherein the risk evaluation comprises normalizing the component ARTERIORISKMARKER measurements to reference values.  
     
     
         50 . The method of  claim 45 , wherein one of the component ARTERIORISKMARKERS is POMC.  
     
     
         51 . The method of  claim 45 , wherein one of the component ARTERIORISKMARKERS is HDLC.  
     
     
         52 . The method of  claim 45 , wherein one of the component ARTERIORISKMARKERS is VEGF.  
     
     
         53 . The method of  claim 45 , wherein one of the component ARTERIORISKMARKERS is CCL2.  
     
     
         54 . The method of  claim 50 , wherein one of the component ARTERIORISKMARKERS is HDLC.  
     
     
         55 . The method of  claim 50 , wherein one of the component ARTERIORISKMARKERS is VEGF.  
     
     
         56 . The method of  claim 50 , wherein one of the component ARTERIORISKMARKERS is CCL2.  
     
     
         57 . The method of  claim 51 , wherein one of the component ARTERIORISKMARKERS is VEGF.  
     
     
         58 . The method of  claim 51 , wherein one of the component ARTERIORISKMARKERS is CCL2.  
     
     
         59 . The method of  claim 52 , wherein one of the component ARTERIORISKMARKERS is CCL2.

Join the waitlist — get patent alerts

Track US2008057590A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.